Michael Asamoah-Boaheng

Mr. Michael Asamoah-Boaheng


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Clinical Epidemiology
Verified
Journal Article
Open access
PDF file
MAMichael Asamoah-Boaheng
Michael Asamoah-Boaheng
KBKwadwo Osei Bonsu
Kwadwo Osei Bonsu
JFJamie Farrell
Jamie Farrell
AOAlwell Oyet
Alwell Oyet
WMWilliam K Midodzi
William K Midodzi
Background: Limited studies have systematically reviewed the literature to identify and compare the various database methods and optimal thresholds for measuring medication adherence specific to adolescents and adults with asthma. In the present study, we aim to identify the methods and optimal thresholds for measuring medication adherence in population-based pharmacy databases. Methods: We searched PubMed, Embase, International Pharmaceutical Abstracts (IPA), Web of Science, Google Scholar, and grey literature from January 1, 1998, to March 16, 2021. Two independent reviewers screened the studies, extracted the data, and assessed the quality of the studies. A quantitative knowledge synthesis was employed. Results: Thirty-eight (38) retrospective cohort studies were eligible. This review identified 20 methods for measuring medication adherence in adolescent and adult asthma administrative health records. Two measures namely the medication possession ratio (MPR) and proportion of days covered (PDC) were commonly reported in 87% of the literature included in this study. From the meta-analysis, asthma patients who achieved adherence threshold of “ 0.75– 1.00” [OR: 0.56, 95% CI: 0.41 to 0.77] and “> 0.5” [OR: 0.71, 95% CI: 0.54 to 0.94] were less likely to experience asthma exacerbation. Conclusion: Despite their limitations, the PDC and the MPR still remain the most common measures for assessing adherence in asthma pharmacy claim databases. The evidence synthesis showed that an adherence threshold of at least 0.75 is optimal for classifying adherent and non-adherent asthma patients.

5 October 2022 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
MAMichael Asamoah-Boaheng
Michael Asamoah-Boaheng
DGDavid M Goldfarb
David M Goldfarb
MKMohammad Ehsanul Karim
Mohammad Ehsanul Karim
SOSheila F O’bRien
Sheila F O’bRien
NWNechelle Wall
Nechelle Wall
BGBrian Grunau
Brian Grunau
The relationship between antibodies to wild-type severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigens and the risk of breakthrough infections is unclear, especially during circulation of the Omicron strain. We investigated the association of anti-spike and anti-receptor binding domain antibody levels and the risk of subsequent breakthrough coronavirus disease 2019 (COVID-19). We included adult paramedics from an observational cohort study who received ≥ 2 mRNA vaccines but did not have COVID-19 before the blood collection. Higher postvaccination antibody levels to wild-type SARS-CoV-2 antigens were associated with a reduced risk of COVID-19. Further research into clinical utility of antibody levels, to inform a threshold for protection and timing of boosters, should be prioritized.

1 October 2018 in International Journal of Epidemiology
Verified
Journal Article
Closed access
PDF file
MAMichael Asamoah-Boaheng
Michael Asamoah-Boaheng
LALily Acheampong
Lily Acheampong
ETEmmanuel Tenkorang
Emmanuel Tenkorang
JFJamie Farrell
Jamie Farrell
AOAlwell Oyet
Alwell Oyet
WMWilliam K Midodzi
William K Midodzi
Whereas most studies have reported prior history/diagnosis of asthma as an independent risk factor for Chronic Obstructive Pulmonary Disease (COPD) development in later life, no systematic review and meta-analysis has been conducted to synthesize these observational studies. The aim of this review is to investigate associations between prior history of asthma and later development of COPD. We conducted a comprehensive search in PubMed, CINAHL and EMBASE for studies related to prior history of asthma and COPD diagnosis. Articles were screened for relevance by two independent reviewers. Methodological quality was independently assessed and data extracted for qualitative and quantitative review. We explored heterogeneity and performed a publication bias check. From the 1260 articles retrieved, 9 were included in the qualitative review and 7 in the meta-analysis. History of asthma was associated with developing COPD in later life (Inverse Variance Random-effects model, odds ratio: 7.87, 95% confidence interval: 5.40–11.45, p < 0.00001). Studies with high methodological quality provided sufficient evidence to suggest that individuals with previous history of asthma have an increasing likelihood of developing COPD in later life.

8 September 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
MAMichael Asamoah-Boaheng
Michael Asamoah-Boaheng
BGBrian Grunau
Brian Grunau
MKMohammad Ehsanul Karim
Mohammad Ehsanul Karim
AJAgatha N. Jassem
Agatha N. Jassem
JBJennifer Bolster
Jennifer Bolster
DGDavid M. Goldfarb
David M. Goldfarb
The SARS-CoV-2 belongs to the coronavirus family, which also includes common endemic coronaviruses (HCoVs). We hypothesized that immunity to HCoVs would be associated with stronger immunogenicity from SARS-CoV-2 vaccines. The study included samples from the COSRIP observational cohort study of adult paramedics in Canada. Participants provided blood samples, questionnaire data, and results of COVID-19 testing. Samples were tested for anti-spike IgG against SARS-CoV-2, HCoV-229E, HCoV-HKU1, HCoV-NL63, and HCoV-OC43 antigens. We first compared samples from vaccinated and unvaccinated participants, to determine which HCoV antibodies were affected by vaccination. We created scatter plots and performed correlation analysis to estimate the extent of the linear relationship between HCoVs and SARS-CoV-2 anti-spike antibodies. Further, using adjusted log-log multiple regression, we modeled the association between each strain of HCoV and SARS-CoV-2 antibodies. Of 1510 participants (mean age of 39 years), 94 (6.2%) had a history of COVID-19. There were significant differences between vaccinated and unvaccinated participant in anti-spike antibodies to HCoV-HKU1, and HCoV-OC43; however, levels for HCoV-229E and HCoV-NL63 were similar (suggesting that vaccination did not affect these baseline values). Among vaccinated individuals without prior COVID-19 infection, SARS-COV-2 anti-spike IgG demonstrated a weak positive relationship between both HCoV-229E (r = 0.11) and HCoV-NL63 (r = 0.12). From the adjusted log-log multiple regression model, higher HCoV-229E and HCoV-NL63 anti-spike IgG antibodies were associated with increased SARS-COV-2 anti-spike IgG antibodies. Vaccination appears to result in measurable increases in HCoV-HKU1, and HCoV-OC43 IgG levels. Anti-HCoV-229E and HCoV-NL63 antibodies were unaffected by vaccination, and higher levels were associated with significantly higher COVID-19 vaccine-induced SARS-COV-2 antibodies.

1 May 2020 in Health Psychology
Verified
Journal Article
Closed access
MHMohammad A. Hossain
Mohammad A. Hossain
MAMichael Asamoah-Boaheng
Michael Asamoah-Boaheng
OBOluwatosin A. Badejo
Oluwatosin A. Badejo
LBLouise V. Bell
Louise V. Bell
NBNorman Buckley
Norman Buckley
JRJoshua Rash
Joshua Rash
This review quantified prescriber adherence to opioid prescribing guidelines for chronic noncancer pain (CNCP). We searched CINAHL, Embase, MEDLINE, PsycINFO, the Cochrane Library, and the Joanna Briggs Institute EBP Database from inception until June 3, 2019. Studies that focused on provider adherence to opioids guidelines for CNCP in North America were eligible. Four reviewers screened studies, extracted data, and assessed study quality. Thirty-eight studies were eligible, comprising 17 cross-sectional studies (n = 11,835 providers) and 22 chart reviews (n = 22,512 patients). Survey data indicated that adherence was 49% (95% CI [40, 59]) for treatment agreements, 33% (95% CI [19%, 47%]) for urine drug testing, 48% (95% CI [26%, 71%]) for consultation with drug monitoring program, 57% (95% CI [35%, 79%]) for assessing risk of aberrant medication-taking behavior, and 61% (95% CI [35%, 87%]) for mental health screening. Chart review data indicated that the proportion of patients with documentation was 40% (95% CI [29, 51]) for treatment agreements, 41% (95% CI [32%, 50%]) for urine drug testing, 40% (95% CI [2%, 78%]) for consultation with drug monitoring program, 41% (95% CI [20%, 64%]) for assessing risk of aberrant medication-taking behavior, and 22% (95% CI [9%, 33%]) for mental health screening. Year of publication, practice guideline referenced, and risk of bias explained significant heterogeneity. No study evaluated whether nonadherence to recommendations reflected well-justified deviations to care. Adherence to guideline recommendations for opioids for CNCP is low. It is unclear whether nonadherence reflects thoughtful deviations in care. (PsycInfo Database Record (c) 2020 APA, all rights reserved).

23 February 2022 in Microbiology Spectrum
Verified
Journal Article
Open access
MAMichael Asamoah-Boaheng
Michael Asamoah-Boaheng
DGDavid Goldfarb
David Goldfarb
VBVilte Barakauskas
Vilte Barakauskas
TKTracy L. Kirkham
Tracy L. Kirkham
PDPaul A. Demers
Paul A. Demers
BGBrian Grunau
Brian Grunau
Among a cohort of adult paramedics in Canada, we investigated the performance of nucleocapsid (N) antibody detection (measured with a V-PLEX assay) to identify previous COVID-19 infections and compared differences among vaccinated and unvaccinated. Our data indicate that vaccinated and unvaccinated groups require different thresholds to achieve optimal test performance, especially for detecting COVID-19 within the preceding 9 months.